Search results for: 'gene busi'

19 Jan 2023  |  Global  |  Technology Research

Advances in Gene Editing Technologies in Healthcare

Next-generation genome editing tools and improved delivery are bolstering gene editing therapeutics and diagnostics.

Infographics

×

Advancements in gene editing technology are boosting its adoption in various fields, including healthcare, diagnostics, agriculture, and industrial biotechnology. CRISPR, ZFNs, and TALENs are examples of technologies that have revolutionized the gene editing field. Moreover, with constant research efforts, new technologies such as base editing, pri...

12 May 2016  |  Global  |  Market Research

Global Business Aircraft Market, Forecast to 2020

Maintenance, Repair, and Overhaul (MRO) and Modification Programs Emerge as Pockets of Revenue Growth Amid Softening Environment

Infographics

×

This research service on the global business aircraft market provides detailed market forecasts and drivers and restraints as well as market shares and competitive analyses of participants from 2015 to 2020. This study covers 4 market segments: heavy aircraft, medium aircraft, light aircraft, and turboprop aircraft. Additionally, this study present...

The global CGT therapeutics market is transitioning from a niche, high-complexity segment into a mainstream, high-growth therapeutic class. Driven by scientific breakthroughs, accelerated regulatory pathways, and the entry of next-generation platforms—including in vivo CRISPR gene editing, allogeneic “off-the-shelf” cell therapies, and automated sm...

This study offers an overview of the changing business outlooks, which gave rise to new operating strategies and advanced techniques for building a resilient business model. These business outlooks aid in creating direct opportunities for major sectors, such as technology, energy, industrial, mobility, business and financial services, agriculture, ...

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

Post-pandemic, 2022 has triggered a unique set of challenges that are already causing major disruptions to business. As countries are slowly recovering from the pandemic, year 2022 has already caused severe damage to business confidence, ranging from economic slowdown, to the Russo-Ukrainian War, to supply chain disruptions, to talent shortages, to...

Outsourcing helps organizations navigate the challenging competitive environment. It has evolved from being a resource expansion and cost arbitrage solution to a process that drives business outcomes and creates value for customers. This Frost & Sullivan study presents forecasts for the global business process management (BPM) services market from ...

The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme repl...

16 Aug 2022  |  North America  |  Market Research

Global Cell and Gene Therapy (CGT) Growth Opportunities

The Shift to Prevalent Diseases and Allogeneic Cell Therapies Creates New Growth Opportunities in the CGT Value Chain

Infographics

×

This Frost & Sullivan study examines the global cell and gene therapy (CGT) market. It highlights revenue forecasts and key growth opportunities for CGT market participants based on the evolution of their business models and strategic approaches as well as investments and regulations. The study segments the market by product (cell therapy, gene-mod...